EP3341011A4 - PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents

PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES Download PDF

Info

Publication number
EP3341011A4
EP3341011A4 EP16825301.1A EP16825301A EP3341011A4 EP 3341011 A4 EP3341011 A4 EP 3341011A4 EP 16825301 A EP16825301 A EP 16825301A EP 3341011 A4 EP3341011 A4 EP 3341011A4
Authority
EP
European Patent Office
Prior art keywords
interleukin
receptor
inflammatory diseases
peptide inhibitors
treat inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16825301.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3341011A2 (en
Inventor
Ashok Bhandari
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of EP3341011A2 publication Critical patent/EP3341011A2/en
Publication of EP3341011A4 publication Critical patent/EP3341011A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP16825301.1A 2015-07-15 2016-07-15 PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES Pending EP3341011A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (2)

Publication Number Publication Date
EP3341011A2 EP3341011A2 (en) 2018-07-04
EP3341011A4 true EP3341011A4 (en) 2019-02-20

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16825301.1A Pending EP3341011A4 (en) 2015-07-15 2016-07-15 PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES

Country Status (23)

Country Link
EP (1) EP3341011A4 (zh)
JP (1) JP6858174B2 (zh)
KR (1) KR102513978B1 (zh)
CN (1) CN108348580B (zh)
AU (1) AU2016293619B2 (zh)
BR (1) BR112018000691A2 (zh)
CA (1) CA2991984A1 (zh)
CL (3) CL2018000128A1 (zh)
CO (1) CO2018000349A2 (zh)
CR (1) CR20180029A (zh)
DO (1) DOP2018000010A (zh)
EA (1) EA035733B9 (zh)
EC (1) ECSP18002929A (zh)
HK (2) HK1257747A1 (zh)
IL (1) IL256827A (zh)
MX (1) MX2018000542A (zh)
NI (1) NI201800008A (zh)
PE (1) PE20180571A1 (zh)
PH (1) PH12018500086A1 (zh)
SG (1) SG10201912066SA (zh)
SV (1) SV2018005614A (zh)
UA (1) UA123772C2 (zh)
WO (1) WO2017011820A2 (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007951A2 (en) 2012-06-13 2014-01-09 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
KR102482790B1 (ko) 2014-07-17 2022-12-29 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
NZ773116A (en) 2015-02-20 2024-05-31 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
AU2018210174B2 (en) * 2017-01-18 2022-04-07 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
CN115298196A (zh) * 2020-01-15 2022-11-04 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
IL302996A (en) * 2020-11-20 2023-07-01 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of the interleukin-23 receptor
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20240034223A (ko) * 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제
CA3240982A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists
US20240218014A1 (en) * 2022-11-21 2024-07-04 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
WO2024155547A2 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor
WO2024163643A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183755A1 (en) * 2010-03-31 2013-07-18 Grant Gallagher Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2288621A4 (en) * 2007-07-06 2012-01-04 Valorisation Hsj Soc En Commandite IL23 RECEPTOR ANTAGONISTS AND THEIR USE
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183755A1 (en) * 2010-03-31 2013-07-18 Grant Gallagher Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017011820A2 *

Also Published As

Publication number Publication date
IL256827A (en) 2018-03-29
JP6858174B2 (ja) 2021-04-14
BR112018000691A2 (pt) 2018-09-18
CN108348580A (zh) 2018-07-31
KR102513978B1 (ko) 2023-03-27
MX2018000542A (es) 2018-06-27
SG10201912066SA (en) 2020-02-27
HK1259149A1 (zh) 2019-11-29
EP3341011A2 (en) 2018-07-04
KR20180030663A (ko) 2018-03-23
CL2021000343A1 (es) 2021-08-06
SV2018005614A (es) 2018-05-22
NI201800008A (es) 2018-06-29
EA201890325A1 (ru) 2018-06-29
EA035733B1 (ru) 2020-07-31
CL2018000128A1 (es) 2018-06-15
CN108348580B (zh) 2022-05-10
PH12018500086A1 (en) 2018-07-30
CA2991984A1 (en) 2017-01-19
CL2018003322A1 (es) 2019-01-18
CR20180029A (es) 2018-06-05
ECSP18002929A (es) 2018-03-31
DOP2018000010A (es) 2018-03-30
EA035733B9 (ru) 2021-01-14
PE20180571A1 (es) 2018-04-04
HK1257747A1 (zh) 2019-10-25
JP2018522008A (ja) 2018-08-09
AU2016293619B2 (en) 2021-02-25
CO2018000349A2 (es) 2018-07-10
WO2017011820A3 (en) 2017-02-23
UA123772C2 (uk) 2021-06-02
WO2017011820A2 (en) 2017-01-19
AU2016293619A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
HK1259149A1 (zh) 白細胞介素-23受體的肽抑制劑以及其治療炎症性疾病的用途
IL285614A (en) Oral peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory bowel diseases
EP3570864A4 (en) INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE IN THE TREATMENT OF FLAMMABLE DISEASES
EP3820883A4 (en) PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
IL253796A0 (en) Therapeutically active compounds and methods of use
IL251246A0 (en) Therapeutically active compounds and methods of use
EP3151833A4 (en) Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
IL250318B (en) Protein kinase c inhibitors and methods of using them
EP3047024A4 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
EP3116898A4 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
HK1211471A1 (zh) 通過抑制含布羅莫結構域蛋白 治療 介導的疾病
IL289628A (en) Peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory diseases
IL253118A0 (en) Methods for treating inflammatory diseases
HK1252037A1 (zh) 治療炎性疾病的方法
EP3157531A4 (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
EP3503903A4 (en) ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
EP3148575A4 (en) Methods and compositions for treating allergy and inflammatory diseases
EP3408413A4 (en) PREDICTING A THERAPEUTIC RESPONSE IN INFLAMMATORY CONDITIONS
EP3288379A4 (en) Peptide compositions and methods of use
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
EP3393460A4 (en) COMPOSITIONS AND METHODS FOR TREATING MVID AND RELATED DISEASES
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
EP3139944A4 (en) Use of peptide for treating angiogenesis-related diseases
IL241934A (en) Inhibitory peptides for the treatment of inflammatory diseases
EP3534932A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH IGFB3 AND ITS RECEPTOR

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190121

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/08 20060101ALI20190115BHEP

Ipc: A61K 38/20 20060101AFI20190115BHEP

Ipc: C07K 14/54 20060101ALI20190115BHEP

Ipc: C07K 7/06 20060101ALI20190115BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257747

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTAGONIST THERAPEUTICS, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038200000

Ipc: C07K0007060000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALN20240724BHEP

Ipc: A61P 37/06 20060101ALI20240724BHEP

Ipc: A61P 37/02 20060101ALI20240724BHEP

Ipc: A61P 35/00 20060101ALI20240724BHEP

Ipc: A61P 29/00 20060101ALI20240724BHEP

Ipc: A61P 19/02 20060101ALI20240724BHEP

Ipc: A61P 17/06 20060101ALI20240724BHEP

Ipc: A61P 15/00 20060101ALI20240724BHEP

Ipc: A61P 11/06 20060101ALI20240724BHEP

Ipc: A61P 11/02 20060101ALI20240724BHEP

Ipc: A61P 7/00 20060101ALI20240724BHEP

Ipc: A61P 3/10 20060101ALI20240724BHEP

Ipc: A61P 3/00 20060101ALI20240724BHEP

Ipc: A61P 1/18 20060101ALI20240724BHEP

Ipc: A61P 1/16 20060101ALI20240724BHEP

Ipc: A61P 1/04 20060101ALI20240724BHEP

Ipc: C07K 7/08 20060101ALI20240724BHEP

Ipc: C07K 7/06 20060101AFI20240724BHEP

INTG Intention to grant announced

Effective date: 20240806